Drug Profile
Prosaptide TX 152
Latest Information Update: 24 Jan 2001
Price :
$50
*
At a glance
- Originator Myelos Corporation
- Class Nerve growth factors
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 24 Jan 2001 Discontinued-Preclinical for CNS disorders in USA (Unknown route)
- 08 Aug 2000 Preclinical development for CNS disorders in USA (Unknown route)